Guggenheim Raises Price Target on Amgen (AMGN)

Guggenheim Raises Price Target on Amgen (AMGN)


Guggenheim reported on Tuesday that they have increased their price target on biotechnology medicines company, Amgen, Inc.(AMGN).

The firm, which currently has a “Neutral” rating on AMGN, has raised the company’s price target to $95. This price target suggests a 5% upside to the stock’s current price of $89.55.

Analysts have increased the company’s price target due to the company’s decreased competition which occurred after the recall of Omonty.

Amgen shares were mostly flat during premarket trading Tuesday. The stock has increased 32% in the past year.

The Bottom Line
Shares of Amgen, Inc.(AMGN) have a 2.10% yield, based on Monday’s closing price of $89.55.

Amgen, Inc.(AMGN) is not recommended at this time, holding a DARS™ Rating of 3.4 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.

Free Updates

Join over 100,000 investors who get the latest news from

Best Dividend Stocks

Looking for stocks that are poised for growth and pay solid dividends? Visit our list of the:

Best Dividend Stocks

Partner Center

Best CD Rates

Sitting on some extra cash and looking for the most current and profitable CD Rates?

Get The Best CD Rates

14 Day Free Trial

Earn more from your dividend portfolio within the next 14 days.

Sign Up Today